These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 668783)

  • 1. Effect of sulphinpyrazone (Anturan) on uric acid excretion and plasma uric acid concentration in healthy volunteers.
    Pfister B; Imhof P; Wirz H
    Eur J Clin Pharmacol; 1978 Jun; 13(4):263-5. PubMed ID: 668783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for a postsecretory reabsorptive site for uric acid in man.
    Diamond HS; Paolino JS
    J Clin Invest; 1973 Jun; 52(6):1491-9. PubMed ID: 4703233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects.
    Shen Z; Gillen M; Miner JN; Bucci G; Wilson DM; Hall JW
    Drug Des Devel Ther; 2017; 11():2077-2086. PubMed ID: 28744099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldose reductase inhibitory and uricosuric activities of FK366 in healthy volunteers.
    Kanamaru M; Uematsu T; Nagashima S; Mizuno A; Terakawa M; Sugiyama A; Nakashima M
    J Clin Pharmacol; 1993 Nov; 33(11):1122-31. PubMed ID: 8300896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of orally administered sulphinpyrazone (Anturan) on platelet aggregation in vitro.
    Pfister B; Godbillon J; Colussi D; Imhof P
    Thromb Res; 1980 Apr 1-15; 18(1-2):89-99. PubMed ID: 7404507
    [No Abstract]   [Full Text] [Related]  

  • 6. A study of the effect of sulphinpyrazone ('Anturan') on blood viscosity.
    Johnston RV; Lowe GD; Drummond MM; Forbes CD; Prentice CR
    Curr Med Res Opin; 1979; 6(4):271-3. PubMed ID: 527353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the uricosuric effect of sulfinpyrazone (anturan) and zoxazolamine (flexin).
    MONTGOMERY DB; OGRYZLO MA
    Can Med Assoc J; 1960 Oct; 83(17):885-8. PubMed ID: 13772195
    [No Abstract]   [Full Text] [Related]  

  • 8. Sulphinpyrazone metabolism during long-term therapy.
    Pedersen AK; Jakobsen P
    Br J Clin Pharmacol; 1981 Jun; 11(6):597-603. PubMed ID: 7272176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulphinpyrazone, aspirin, and uric acid.
    Newland HR
    Lancet; 1980 Apr; 1(8171):770. PubMed ID: 6103187
    [No Abstract]   [Full Text] [Related]  

  • 10. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects.
    Nakashima M; Uematsu T; Kosuge K; Kanamaru M
    Eur J Clin Pharmacol; 1992; 42(3):333-5. PubMed ID: 1577054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of transtubular transport inhibitors in the renal excretion of uric acid in the rat].
    Boudry JF
    Pflugers Arch; 1971; 328(4):279-91. PubMed ID: 5107270
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of sulphinpyrazone on oxidative drug metabolism in man: inhibition of tolbutamide elimination.
    Miners JO; Foenander T; Wanwimolruk S; Gallus AS; Birkett DJ
    Eur J Clin Pharmacol; 1982; 22(4):321-6. PubMed ID: 7106168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of different doses of Irtemazole in repeated application.
    Kamilli I; Gresser U; Zöllner N
    Z Rheumatol; 1991; 50(1):23-8. PubMed ID: 1905451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of trimethoprim on potassium and uric acid metabolism in normal human subjects.
    Don BR
    Clin Nephrol; 2001 Jan; 55(1):45-52. PubMed ID: 11200867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males.
    Shen Z; Rowlings C; Kerr B; Hingorani V; Manhard K; Quart B; Yeh LT; Storgard C
    Drug Des Devel Ther; 2015; 9():3423-34. PubMed ID: 26170627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of uricosuric activity of sulfinpyrazone in healthy adults.
    Malamos B; Sfikakis P; Tsekos G; Tasiopoulos T
    Z Rheumaforsch; 1968 Apr; 27(3):125-8. PubMed ID: 5686580
    [No Abstract]   [Full Text] [Related]  

  • 17. Induction of drug metabolizing enzymes by sulfinpyrazone.
    Walter E; Staiger C; de Vries J; Zimmermann R; Weber E
    Eur J Clin Pharmacol; 1981; 19(5):353-8. PubMed ID: 6113147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic approach to the maintenance of urate homeostasis.
    Kelley WN
    Nephron; 1975; 14(1):99-115. PubMed ID: 1091870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship of sex steroids to uric acid levels in plasma and urine.
    Adamopoulos D; Vlassopoulos C; Seitanides B; Contoyiannis P; Vassilopoulos P
    Acta Endocrinol (Copenh); 1977 May; 85(1):198-208. PubMed ID: 577077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of a vegetarian and different omnivorous diets on urinary risk factors for uric acid stone formation.
    Siener R; Hesse A
    Eur J Nutr; 2003 Dec; 42(6):332-7. PubMed ID: 14673606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.